Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: Case studies and a review of the literature

Aurore Siegfried, Anne Isabelle Bertozzi, Franck Bourdeaut, Annick Sevely, Najat Loukh, Camille Grison, Catherine Miquel, Delphine Lafon, Nicolas Sevenet, Torsten Pietsch, Christelle Dufour, Marie Bernadette Delisle

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Abstract

    The aim of this study was to better define the clinical and biopathological features of patients with desmoplastic/nodular medulloblastoma (DNMB) and to further characterize this subgroup. 17 children aged < 5 years, with initial DNMB treated according to the HIT-SKK protocol, were evaluated. A retrospective central radiological review, a pathological and immunohistochemical study, and array-CGH and sequencing of germline SUFU and PTCH1 genes were performed. 15 histologically reviewed cases were confirmed as DNMB including three cases of medulloblastoma with extensive nodularity. Median age at diagnosis was 26 months. Radiology showed five cases with a vermis location and one with T2 hyperintensity. All cases showed a SHH immunoprofile. A 9q deletion was found in 6 cases, a MYCN-MYCL amplification in 1 case, and a SUFU germline mutation in 1 case (/9). The presence of SUFU and PTCH1 germline mutations agreed with previous reports. At 3 years, progression-free survival and overallsurvival rates were 72 ± 15% and 85 ± 10%, respectively. The rate of recurrence was relatively high (4 patients). This may have been because chemotherapy was delayed in two cases. Age > 3 years, and residual tumor may also have been an explanation for recurrence.

    Original languageEnglish
    Pages (from-to)106-113
    Number of pages8
    JournalClinical Neuropathology
    Volume35
    Issue number3
    DOIs
    Publication statusPublished - 1 Jan 2016

    Keywords

    • Genomic
    • Pathology
    • Prognosis
    • Treatment
    • desmoplastic medulloblastoma

    Cite this